Clene (CLNN)
(Delayed Data from NSDQ)
$0.34 USD
-0.01 (-3.16%)
Updated May 28, 2024 04:00 PM ET
After-Market: $0.34 0.00 (0.03%) 5:30 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Clene Inc. [CLNN]
Reports for Purchase
Showing records 21 - 40 ( 92 total )
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Significant RESCUE-ALS OLE Survival Benefit Delayed Clinical Worsening
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
No Rescuing of Thesis Needed Here; RESCUE-ALS Updated Data Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
2Q23: ALS Program Progresses Toward Regulatory Meetings, Funds To Mid-2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
2Q23 Results; Prepping For Non-Active Progressive MS Cohort and ALS Regulatory Discussions in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
CNM-Au8 Targets Validated Biomarker; Regulatory View Looks Positive; Target Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Highly Encouraging Plasma NfL Biomarker Results for CNM-Au8 in HEALEY ALS
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
$600k Grant from NMSS Covers Cost of REPAIR-MS Trial''s Cohort 2
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
AAN Highlights CNM-AU8?s Survival Benefit Across Multiple ALS Populations; Path Forward Discussions in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
4Q22: CNM-Au8 Pipeline Progressing Well, Next Catalyst Biogen''s AdComm
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
2022 Results; Time for Regulatory Discussions With Favorable ALS and MS Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
CNM-Au8 Associated with Delayed ALS Clinical Progression at Six Months
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
HEALEY ALS Platform Trial Keeps Delivering; Exploratory Analyses Support CNM-Au8's Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
RESCUE-ALS OLE Evidences CNM-Au8's Long-Term Benefits in Physical Function and Clinical Deterioration
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
CNM-Au8 Preserves Function & Slows Disease Progression in ALS - OLE Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J